Evaluation of an External Quality Assessment Program for HIV Testing in Haiti, 2006–2011

AbstractThe external quality assessment schemes (EQAS) organizer provides a suitable program to monitor and improve the quality of human immunodeficiency virus (HIV) testing laboratories with EQAS panels prepared under various conditions. The aim of the current study was to investigate the effects of human plasma samples on the EQAS results of HIV obtained from hospital-based clinical laboratories.From 2007 to 2009, HIV EQAS panels consisted of four to six samples that consisted of undiluted positive and negative samples and were provided to laboratories twice per year. Up until the first half EQAS in 2008, EQAS panel materials were obtained by converting acid citrate dextrose treated plasma to serum via chemical treatment with CaClApproximately 300 HIV clinical laboratories participated in this program. The overall performance of clinical laboratories was shown to be improved when using unrecalcified plasma panels compared with recalcified panels. Significant differences were observed in EIA analyses of plasma for both positive (p<0.001) and negative (p<0.001) samples between the recalcified and unrecalcified groups.Our finding suggested that defibrination status of EQAS panels might affect the results of anti-HIV EQAS of Korean HIV testing laboratories.

Download Full-text

Discordant findings and error types observed in urine drug screens: An external quality assessment program perspective

Clinica Chimica Acta ◽

10.1016/j.cca.2019.03.1561 ◽

2019 ◽

Vol 493 ◽

pp. S705-S706

Author(s):

P. Yip ◽

J. Stemp ◽

E. Dunn ◽

H. Vandenberghe ◽

D. Konforte

Keyword(s):

Quality Assessment ◽

External Quality Assessment ◽

External Quality ◽

Assessment Program ◽

Urine Drug ◽

Error Types

Download Full-text

Analytical Performance of Ca 19.9, Ca 125 and Ca 15.3 Assays as Observed through an External Quality Assessment Program

The International Journal of Biological Markers ◽

10.1177/172460089400900109 ◽

1994 ◽

Vol 9 (1) ◽

pp. 43-47 ◽

Cited By ~ 5

Author(s):

G.C. Zucchelli ◽

A. Pilo ◽

M.R. Chiesa ◽

S. Masini ◽

A. Clerico

Keyword(s):

Monoclonal Antibody ◽

Quality Control ◽

Quality Assessment ◽

External Quality Assessment ◽

Ca 125 ◽

External Quality ◽

Ca 15.3 ◽

Assessment Program ◽

Ca 19.9 ◽

Control Samples

Immunoassays of the tumor markers CA 19.9, CA125 and CA 15.3 are generally acknowledged to be a useful tool in the management of cancer patients. As a consequence, many methods developed by different companies are now commercially available. However, discrepancies have been described in the results of marker determinations even when the same monoclonal antibody was used. An external quality assessment (EQA) was carried out; starting from 1989 about 110 laboratories participated; since December 1991 the program was linked with the interlaboratory program Oncocheck organized by the Service de Radiopharmacie et Radioanalyse, University of Lyon. At present more than 200 laboratories of many European countries are involved: cumulatively 47 quality control samples have been prepared and sent to the participants. This manuscript is a report on data collected for CA 19.9, CA 125, and CA 15.3.

Download Full-text